Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of autoimmune diseases. The company’s lead pipeline program, NKX019, is a chimeric antigen receptor (CAR) NK cell candidate targeting the CD19 antigen to eliminate pathologic B cells in conditions such as lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and antineutrophil cytoplasmic antibody-associated vasculitis. Nkarta utilizes a proprietary modular engineering platform that enhances NK cell recognition and fitness, allowing for scaled manufacturing and cryopreservation to provide an on-demand therapeutic option. The company maintains good manufacturing practice facilities in South San Francisco, California, to produce clinical and potential commercial supply. NKX019 is currently undergoing Phase 1 clinical trials, including Ntrust-1 and Ntrust-2, as well as investigator-sponsored trials for systemic lupus erythematosus and myasthenia gravis. The company previously developed NKX101, a CAR NK candidate targeting NKG2D ligands for hematologic malignancies, which has been deprioritized to focus resources on autoimmune indications. Nkarta’s approach offers a broadly accessible cell therapy that can be administered in outpatient settings, distinct from autologous cell therapies that require individualized manufacturing.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage nkartatx.com
Sector Healthcare IR page ir.nkartatx.com
Tags
cell therapy, natural killer cells, car nk, autoimmune diseases, lupus nephritis, systemic sclerosis, myasthenia gravis, allogeneic, off-the-shelf, cd19 targeting, NKX019, NKX101, Ntrust-1, Ntrust-2
Press page —

Metrics

Valuation  
Market cap $ 187.866M
Market cap (USD) $ 187.866M
P/E -1.51
PEG —
P/BV 0.87
P/S —
P/OCF -1.88
P/FCF -1.84
Dividend yield —
Turnover / mcap —
Returns  
ROE -28.9%
ROI -30.4%
ROIC -26.7%
Profit margin —
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 11
Quality score -41.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 0 0 — — — — 115K
Net profit -104.084M -108.79M -117.501M -113.837M -86.075M -91.361M -21.076M
Free cash flow -89.907M -104.105M -114.307M -104.111M -72.952M -51.017M -20.295M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 1.85 2.49 6.6 5.99 15.35 61.47 31.69
Price performance 12m -0.26 -0.62 0.1 -0.61 -0.75 0.94 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) 7.3M 8.92M 12.5M 82.9M 88.3M 80.3M 76.4M
Cash and deposits (USD) 20.6M 96.7M 60.8M 37.5M 31M 27.9M 39.6M
Right-of-use assets (USD) 7.14M 8.51M 11.7M 45.7M 39.9M 36M 34.4M
Cash flow detail
Operating cash flow (USD) -18.4M -43.5M -67.9M -57M -86.2M -99.7M -88.7M
Purchases of property, plant and equipment (USD) -1.93M -7.51M -5.03M -47.1M -28.1M -4.41M -1.21M
Share-based compensation (USD) 947,000 6.75M 14.5M 16.9M 17.2M 16.7M 8.56M
Free cash flow (OCF - PPE - intangibles) (USD) -20.3M -51M -73M -104M -114M -104M -89.9M
Income detail
Research and development expense (USD) 17.2M 36.2M 63.4M 90.9M 96.8M 96.7M 90.4M
↳ 5y CAGR +41.2% +20.1%
Total comprehensive income (USD) -21.1M -91.4M -86.2M -114M -117M -108M -104M
Comprehensive income to owners (USD) -21.1M -91.4M -86.2M -114M -117M -108M -104M
Reported Mar 25, 2021 Mar 25, 2021 Mar 17, 2022 Mar 16, 2023 Mar 21, 2024 Mar 26, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nkarta Announces Initial Clinical Data for NKX019 Bull 6 Bear 0 Clinical/regulatory

in Myositis and Systemic Sclerosis at ACR Convergence

•In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of NKX019, an investigational, allogeneic CAR NK cell therapy.

•In systemic sclerosis, 6/7 (86%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved a revised Composite Response Index in Systemic Sclerosis (rCRISS)-25 response or greater, with 5/7 (71%) patients achieving an rCRISS-50 response or greater.

•Rapid and deep skin responses observed in systemic sclerosis at 4 billion cells per dose, including a median 15-point reduction in modified Rodnan skin score (mRSS) at Day 90, with 5/7 (71%) patients achieving a reduction of at least 50% from baseline.

SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis being presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.

Live Webcast

To access the webcast, please register through this link: https://nkarta-clinical-update-acr-convergence-2026.open-exchange.net/

A replay will be archived on the Investors section of Nkarta’s website, www.nkartatx.com.

About the Ntrust℠ Clinical Trials in Autoimmune Disease

Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935) are multi-center, open-label, dose-escalation clinical trials in patients with autoimmune disease receiving lymphodepletion followed by CD19-targeted CAR-NK cell therapy.

Nkarta Reports Third Quarter 2026 Financial Results Bull 1 Bear 2 Results

and Provides Business Update

•Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026

•Cash balance of $216.0 million on September 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029

SOUTH SAN FRANCISCO, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026.

"NKX019 is advancing in our two lead indications, myositis and systemic sclerosis," said Paul J. Hastings, Chief Executive Officer of Nkarta. "We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando. We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients.

Prompts

Nkarta, Inc. (ticker NKTX), listed in United States.

ETFs Holding Nkarta, Inc.

ETF Weight in ETF Shares Market value As of
FSEV 0.05% 1,255 $ 3,551.65 Jun 30, 2026
DFAS 0.00% 207,172 $ 262.073K Nov 12, 2026
DXUV 0.00% 25,956 $ 32.834K Nov 12, 2026
DCOR 0.00% 6,031 $ 7,629.22 Nov 12, 2026
DFAC 0.00% 6,442 $ 8,149.13 Nov 12, 2026
AVUS 0.00% 3,657 $ 4,424.97 Nov 16, 2026
AVSC 0.00% 90,267 $ 109.223K Nov 16, 2026